The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Emerging ibrutinib-based combinations in CLL
Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, comments on promising ibrutinib-based combinations under development for the treatment of chronic lymphocytic leukemia (CLL), including doublet therapies such as venetoclax-ibrutinib, or triplet combinations such as ibrutinib-venetoclax-obinutuzumab, and more novel strategies combining ibrutinib with bispecific antibodies. In the future, ibrutinib may be combined with newer BTK inhibitors. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
